A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections

(2012) Andres Pascual et al.   CLINICAL INFECTIOUS DISEASES

Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug–drug interaction

(2012) Isabel Spriet et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects

(2011) Grant Langdon et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients

(2011) Kelong Han et al.   CLINICAL PHARMACOKINETICS

Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

(2011) S Katzenmaier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of the Intestinal First-pass Metabolism of CYP3A and UGT Substrates in Humans from in vitro Data

(2011) Haruka Nishimuta et al.   Drug Metabolism and Pharmacokinetics

Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients

(2010) K. Han et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models

(2010) Eleanor J. Guest et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles

(2010) Hiroshi Yamazaki et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling

(2010) Nathalie Perdaems et al.   CLINICAL PHARMACOKINETICS

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Theoretical Considerations on Quantitative Prediction of Drug-Drug Interactions

(2010) Akihiro Hisaka et al.   Drug Metabolism and Pharmacokinetics

Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions

(2010) Aleksandra Galetin et al.   Drug Metabolism and Pharmacokinetics

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

(2010) Hui-Yan Shi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors

(2010) Yuping Liu et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

In Vitro-In Vivo Extrapolation Predicts Drug-Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans

(2010) P. Raungrut et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Sources of variability in ketoconazole inhibition of human cytochrome P450 3Ain vitro

(2010) David J. Greenblatt et al.   XENOBIOTICA

In vitroandin vivoglucuronidation of midazolam in humans

(2009) Ruth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling

(2009) Akihiro Hisaka et al.   CLINICAL PHARMACOKINETICS

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam

(2009) Karen Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study

(2009) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information

(2009) Akihiro Hisaka et al.   PHARMACOLOGY & THERAPEUTICS

Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies

(2008) M. O. Karlsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A

(2008) S. Jeong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations

(2008) Michael Gertz et al.   CURRENT DRUG METABOLISM

Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans

(2008) S. Klieber et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

(2008) P. J. Kilford et al.   DRUG METABOLISM AND DISPOSITION

Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

(2008) Aleksandra Galetin et al.   Expert Opinion on Drug Metabolism & Toxicology

Extensions to the Visual Predictive Check to facilitate model performance evaluation

(2008) Teun M. Post et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS